Preparation characterization intravenous solution IgG human immunodeficiency virus-seropositive donors intravenous solution pure globulin hyperimmune IgG HIVIG pooled plasma human immunodeficiency virus asymptomatic donors cells microliter high titer antibody protein HIVIG high titers antibody group-specific neutralizing activity hypervariable loop region syncytia formation low concentration viral production infected peripheral blood monocytes inhibitory concentration HIVIG group-specific antibody-dependent cellular cytotoxicity HIV-infected targets period months plasma donors stable antibody titers decrease cells month gram kilogram HIVIG juvenile chimpanzees HIV negative cell culture IgM response HIV proteins polymerase chain reaction mean half-life antibody days preliminary data HIVIG safe product suitable clinical trial individuals 